Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?
Alan O, Akin Telli T, Aktas B, Koca S, Ökten IN, Hasanov R, Basoglu T, Arikan R, Demircan NC, Ercelep O, Kaya S, Ugurlu MU, Kaya H, Akgul Babacan N, Dane F, Yumuk PF. Alan O, et al. Among authors: kaya h, kaya s. World J Surg Oncol. 2020 Sep 9;18(1):242. doi: 10.1186/s12957-020-02019-y. World J Surg Oncol. 2020. PMID: 32907593 Free PMC article.
Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study.
Demirci A, Alkış N, Dane F, Durnalı A, Yazıcı ÖK, Rzayev R, Kaya S, Yazılıtaş D, İnanç M, Özçelik M, Akman T, Kaplan MA, Günaydın Y, Ulaş A, Sönmez Ö, Tokluoğlu S, Gököz Doğu G, Bal Ö, Gümüş M. Demirci A, et al. Among authors: kaya s. Asia Pac J Clin Oncol. 2018 Apr;14(2):e145-e151. doi: 10.1111/ajco.12685. Epub 2017 Apr 21. Asia Pac J Clin Oncol. 2018. PMID: 28429422
How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.
Alan O, Kuzhan O, Koca S, Telli TA, Basoglu T, Ercelep O, Filinte D, Sengul Y, Arikan H, Kaya S, Babacan NA, Dane F, Yumuk PF. Alan O, et al. Among authors: kaya s. J Oncol Pharm Pract. 2020 Jun;26(4):1011-1018. doi: 10.1177/1078155219879757. Epub 2019 Oct 15. J Oncol Pharm Pract. 2020. PMID: 31615346 Review.
Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib.
Demircan NC, Alan Ö, Başoğlu Tüylü T, Akın Telli T, Arıkan R, Çiçek FC, Ercelep Ö, Öztürk MA, Alsan Çetin İ, Ergelen R, Tinay İ, Akgül Babacan N, Kaya S, Dane F, Yumuk PF. Demircan NC, et al. Among authors: kaya s. J Oncol Pharm Pract. 2020 Jul;26(5):1147-1155. doi: 10.1177/1078155219890032. Epub 2019 Dec 2. J Oncol Pharm Pract. 2020. PMID: 31793376
Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer.
Demirelli B, Babacan NA, Ercelep Ö, Öztürk MA, Kaya S, Tanrıkulu E, Khalil S, Hasanov R, Alan Ö, Telli TA, Koca S, Arıbal ME, Kuzan B, Dane F, Yumuk PF. Demirelli B, et al. Among authors: kaya s. Nutr Cancer. 2021;73(2):230-238. doi: 10.1080/01635581.2020.1749290. Epub 2020 Apr 9. Nutr Cancer. 2021. PMID: 32270713
1,268 results